Office-based treatment of opiate-dependent patients with buprenorphine: It's about time

Primary Psychiatry

Volumn 13, Issue 2, 2006, Pages 68-73

  McDowell, David M ^a   Cocke, Cynthia ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST;

ACT; COMORBIDITY; DRUG DETOXIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; GOVERNMENT REGULATION; HUMAN; MAINTENANCE THERAPY; MENTAL DISEASE; MOTIVATION; MOTIVATIONAL ENHANCEMENT THERAPY; OPIATE ADDICTION; OUTPATIENT CARE; PRESCRIPTION; PSYCHOTHERAPY; RELAPSE; REVIEW; SELF CONCEPT; TREATMENT DURATION; UNITED STATES;

EID: 33644516575     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Drug Addiction Treatment Act of 2000. Public Law No. 106-310. XXXV-Waiver authority for physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment Available at: http://www.buprenorphine.samhsa.gov/fulllaw.html. Accessed January 3, 2006.
2. Center for Substance Abuse Treatment, Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. DHHS Publication No. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005.
3. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290-1297.
4. Center for Substance Abuse Treatment. A Guide to Substance Abuse Services fur Primary Care Clinicians. Treatment Improvement Protocol (TIP) Series, Number 24. DHHS Pub. No. (SMA) 97-3139. Washington, DC: US Government Printing Office; 1997.
5. Center for Substance Abuse Treatment. Brief Interventions and Brief Therapies far Substance Abuse. Treatment Improvement Protocol (TIP) Series. DHHS Pub. No. (SMA) 99-3353. Washington, DC: US Government Printing Office; 1999.
6. Clark HW. Office-based practice and opioid-use disorders. N Engl J Med. 2003;349(10):928-930.
7. Brown RL, Rounds LA. Conjoint Screening questionnaires for alcohol and other drug abuse; criterion validity in a primary care practice. Wis Med J. 1995;94(3);135-140.
8. Petry NM, Bickel WK, Piasecki D, Marsch LA, Badger GJ. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000;9(3):265-269.
9. Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G. Fatal Intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci. 2000;45(1):226-228.
10. Reynaud M, Tracqui A, Petit G, Potard D, Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry. 1998;155(3):448-449.
11. Comer SD, Collins ED, Fisctiman MW. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmocology (Berl). 2001;154(1):28-37.
12. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54(8);713-720.
13. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med. 2000;133(1):40-54.
14. Preston KL, Bigelow GE, Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend. 1990;25(1);27-34.
15. Strain EC, Preston KL, Liebson IA, Bigelow GE. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Esp Ther. 1992;261(3):985-993.
16. O'Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105(2):100-105.
17. Marlatt GA, Gordon JR, eds. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York, NY: Guilford Press; 1985.
18. Diagnostic and Statistical Manual of Mental Disorders. 4th ed rev. Washington, DC: American Psychiatric Association; 2000.
19. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opioid dependence: a multicenter, randomized clinical trial. Addiction. 1998;93(4):475-486.
20. Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend. 1994;36(2):115-121.
21. Johnson RE, Cone EJ, Henningfield JE, Fudala PJ. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin Pharmacol Ther. 1989;46(3):335-343.
22. Amass L, Bickel WK, Crean JP, Blake J, Higgins ST. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (Berl). 1998;136(3):217-225.
23. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003:70(2 suppl):S59-S77.
24. Bradley BP, Gossop M, Phillips GT, Legarda JJ. The development of an opiate withdrawal scale (OWS). Br J Addict. 1987;82(10):1139-1142.
25. Bickel WK, Amass L, Crean JP, Badger GJ. Buprenorphine dosing every 1, 2 or 3 days in opioid-dependent patients. Psychopharmacology (Berl). 1999;146(2):111-118.
26. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293-308.
27. Banys P, Clark HW, Tusel DJ, et al. An open trial of low dose buprenorphine in treating methadone withdrawal. J Subst Abuse Treat. 1994;11(1):9-15.
28. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003;70(2 suppl):S87-S101.